Safety and Efficacy Evaluation of IM19 Cells

NCT03344705 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematological Malignancies

Interventions

BIOLOGICAL: IM19 CAR-T
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Beijing Immunochina Medical Science & Technology Co., Ltd.